Literature DB >> 11352307

Clinical presentation and treatment of non-Hodgkin's lymphoma of the thyroid gland.

D A Wirtzfeld1, J S Winston, W L Hicks, T R Loree.   

Abstract

BACKGROUND: Non-Hodgkin's lymphoma (NHL) of the thyroid is a rare malignancy. The traditional approach to curative treatment of localized (stages I and II) NHL of the thyroid gland is surgical resection. The recent success of multimodality chemoradiotherapy suggests that surgery should be reserved for providing a tissue diagnosis or relief from acute airway obstruction. It is questionable whether this has made an impact on treatment approaches.
METHODS: Retrospective chart review was conducted for all cases of localized NHL of the thyroid gland treated at Roswell Park Cancer Institute between January 1970 and January 1999.
RESULTS: Ten patients (8 women, 2 men) with a mean age of 56.8 years were identified. Nine patients (90%) presented with a neck mass; seven patients (70%) had a history of Hashimoto's disease. Nine patients (90%) had extensive investigations to rule out extrathyroidal disease. All patients were treated with either a total thyroidectomy (eight patients) or a thyroid lobectomy (two patients). Nine (90%) were initially treated outside of Roswell Park Cancer Institute and referred secondarily for consideration of further therapy. Adjuvant therapy consisting of cyclophosphamide-based chemoradiotherapy was administered to nine patients. Overall survival was 80% at a mean follow-up of 8.6 years with a disease-specific survival rate of 100%.
CONCLUSIONS: A review of the literature suggests that fine needle aspiration (FNA) with flow cytometry and immunohistochemistry can be used to accurately diagnose NHL of the thyroid gland. Open biopsy should be reserved for cases where this technique is not available or where the diagnosis can not be confirmed by FNA alone. Extrathyroidal NHL should be ruled out by chest x-ray, CT scan of the abdomen, and bone marrow biopsy. Further review suggests that the most efficacious therapy is systemic chemotherapy in combination with radiation for local control. Debulking surgery should be used only to provide relief from acute airway obstruction.

Entities:  

Mesh:

Year:  2001        PMID: 11352307     DOI: 10.1007/s10434-001-0338-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

Review 1.  An evidence-based approach to the treatment of thyroid lymphoma.

Authors:  Lloyd A Mack; Janice L Pasieka
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

2.  Extranodal marginal zone B cell lymphoma of MALT type with extensive plasma cell differentiation in a man with Hashimoto's thyroiditis.

Authors:  Fariba Binesh; Ali Akhavan; Hossein Navabii
Journal:  BMJ Case Rep       Date:  2011-11-01

3.  Outcomes of primary thyroid non-Hodgkin's lymphoma: a series of nine consecutive cases.

Authors:  Milica Colović; Slavko Matić; Emrush Kryeziu; Dragica Tomin; Natasa Colović; Henry Dushan Edward Atkinson
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

4.  Contrast-Enhanced Ultrasound in the Differential Diagnosis of Primary Thyroid Lymphoma and Nodular Hashimoto's Thyroiditis in a Background of Heterogeneous Parenchyma.

Authors:  Lulu Yang; Haina Zhao; Yushuang He; Xianglan Zhu; Can Yue; Yan Luo; Buyun Ma
Journal:  Front Oncol       Date:  2021-01-07       Impact factor: 6.244

Review 5.  Primary thyroid lymphomas.

Authors:  Sandy Widder; Janice L Pasieka
Journal:  Curr Treat Options Oncol       Date:  2004-08

6.  Survival and failure outcomes in primary thyroid lymphomas: a single centre experience of combined modality approach.

Authors:  Ritesh Kumar; Divya Khosla; Narendra Kumar; Sushmita Ghoshal; Anjan Bera; Ashim Das; Suresh Chander Sharma
Journal:  J Thyroid Res       Date:  2013-09-12

Review 7.  Primary Thyroid Extranasal NK/T-Cell Lymphoma Associated With Good Outcome: A Case Report and Literature Review: A Care-Compliant Article.

Authors:  Jun-He Li; Hong-Hong He; Yuan Cheng; Wen-Jing He
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.